Depression

A psychiatrist and their patient reflect on treatment.

What is the current role of lithium?

From gut microbiota and SSRIs in MDD to nonpharmacological interventions following TBI, here are highlights from the week in Psychiatric Times.

The experts weighed in on a wide variety of psychiatric issues for the March 2023 issue of Psychiatric Times.

A gut feeling? Researchers analyzed the gut microbiome in major depression disorder and its modulation by SSRI antidepressants.

New results for a study evaluating lumateperone.

From an update on at-home ketamine therapy to the psychopharmacologic treatment of bipolar depression, here are highlights from the week in Psychiatric Times.

What is the best evidence-based medication treatment for acute bipolar II depression?

Study results show that the therapy activates serotonin (5-HT) and improves stress-coping ability.

The Future of Mental Health: Ketamine Therapy Report revealed that 55% of Americans who tried at home ketamine took more than the recommended dose.

Catch up on the latest CMEs in Psychiatric Times.

Transcranial direct current stimulation for depression.

Lithium: what’s its history and where do we still need more information?

Here are 9 things you need to know about the clinical management of major depressive disorder.

Fatigue is a very common physical complaint. What therapeutic options are available?

From the impact of patients’ overdose deaths on physicians to addressing America’s mental health crisis, here are highlights from the week in Psychiatric Times.

“We are not exempt from these diseases. We have to speak up.”

"The history of medicine is rich in blaming the disease or the patient for 'untreatable' symptoms, until we stumble upon or develop a treatment that is, in fact, effective."

From special issues in diagnosing and treating catatonia to helping justice-involved individuals re-enter the community, here are highlights from the week in Psychiatric Times.

SPL026 with supportive therapy sees positive results in patients with major depressive disorder.

From a new FDA approval to treating “New Year depression” in patients, here are highlights from the week in Psychiatric Times.

Is inflammation a biomarker of antidepressant efficacy? Researchers analyzed blood CRP levels as a predictor of response to antidepressants.

There may not be a diagnosis for ‘New Year Depression,’ about 10% to 20% of individuals in the US may get a milder form of these winter blues.

Metabolic depression? Researchers performed a metabolomic evaluation of patients with treatment-resistant depression.